| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The MDA-MB-468 cells responded to SuLfopin (1, 2.5 μM; 4–8 days) with the greatest body weight [1]. Myc is neatly packaged by SuLfopin (2 μM, HEK293 cells; 48 hours) [1]. 1, 2.5 μM; PATU-8988T cells; 4 days) revealed a commensurate rise in cells in the growth 1 (G1) phase and a minor but noteworthy reduction in the number of cells in the synthesis (S) phase [1].
|
|---|---|
| ln Vivo |
SuLfopin (40 mg/kg; po; QD/BID for 7 days) induces regression of neuroblastoma in mice [1]. SuLfopin (20-40 mg/kg; ip; daily for 27 days) induces regression of neuroblastoma in mice. SuLfopin (25-100 μM) induces neuroblastoma outbreak in zebrafish [1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Kuramochi, MDA-MB-468, NGP, NBL-S, MDA-MB-468 Cell Tested Concentrations: 1, 2.5 μM Incubation Duration: 4, 6, 8 days Experimental Results: Display of different cancer cells There were differences in the antiproliferative effects of the lines Kuramochi, MDA-MB-468, NGP and NBL-S, with the most pronounced sensitivity observed in MDA-MB-468 cells. |
| Animal Protocol |
Animal/Disease Models: transgenic Th-MYCN mice [1]
Doses: 40 mg/kg Route of Administration: one time/day (QD). ) or twice (two times) daily (BID) for 7 days. Experimental Results: The average survival time of Sulfopin-treated QD mice was Dramatically increased by 10 days, while the average survival time of Sulfopin-treated BID mice was Dramatically increased by 28 days. |
| References | |
| Additional Infomation |
Sulfopin is a sulfone that is thiolane substituted by two oxo groups at position 1 and by a (chloroacetyl)(2,2-dimethylpropyl)amino group at position 3. It is a covalent inhibitor of Pin1 (Ki = 17 nM) that inhibits Myc-driven tumors in vivo. It has a role as an EC 5.2.* (cis-trans-isomerase) inhibitor and an antineoplastic agent. It is a member of tetrahydrothiophenes, a sulfone, an organochlorine compound and a tertiary carboxamide.
|
| Molecular Formula |
C11H20CLNO3S
|
|---|---|
| Molecular Weight |
281.799401283264
|
| Exact Mass |
281.09
|
| Elemental Analysis |
C, 46.89; H, 7.15; Cl, 12.58; N, 4.97; O, 17.03; S, 11.38
|
| CAS # |
2451481-08-4
|
| PubChem CID |
155804394
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
381
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NMHVAHHYKGXBMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H20ClNO3S/c1-11(2,3)8-13(10(14)6-12)9-4-5-17(15,16)7-9/h9H,4-8H2,1-3H3
|
| Chemical Name |
2-chloro-N-(1,1-dioxidotetrahydrothiophen-3-yl)-N-neopentylacetamide
|
| Synonyms |
Sulfopin;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~354.86 mM)
H2O : ~4.35 mg/mL (~15.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5486 mL | 17.7431 mL | 35.4862 mL | |
| 5 mM | 0.7097 mL | 3.5486 mL | 7.0972 mL | |
| 10 mM | 0.3549 mL | 1.7743 mL | 3.5486 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
